← Search & browse all drugs
CARDIOVASCULAR SYSTEM › CARDIAC THERAPY › CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES › Phosphodiesterase inhibitors
enoximone
C01CE03
Forms & Strengths
- Intravenous injection: 5 mg/mL
- Intravenous infusion concentrate: 25 mg/mL
- Oral tablets: 50 mg, 100 mg (limited availability/regional)
Adult Dosing
- IV Loading dose: 0.5 to 1.0 mg/kg slowly over 5 to 10 minutes
- IV Maintenance infusion: 5 to 20 mcg/kg/min
- Oral: 50 to 100 mg every 8 hours (if applicable)
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
- Use restricted to specialized pediatric intensive care settings under expert guidance if absolutely necessary
Indications
- Short-term management of acute decompensated heart failure
- Low cardiac output states refractory to standard therapy
Mechanism of Action
- Selective phosphodiesterase 3 (PDE3) inhibitor
- Increases intracellular cAMP in cardiac and vascular smooth muscle
- Produces positive inotropic effect and systemic/pulmonary vasodilation
Contraindications
- Hypersensitivity to enoximone or other PDE inhibitors
- Severe obstructive aortic or pulmonic valvular disease
- Hypertrophic cardiomyopathy where increased contractility is harmful
- Acute myocardial infarction with high risk of arrhythmias
Adverse Reactions
- Ventricular arrhythmias (VT, VF)
- Supraventricular tachycardias
- Hypotension
- Headache
- Thrombocytopenia
- Elevated liver enzymes
Drug Interactions
- Additive hypotensive effects with other vasodilators and antihypertensives
- Increased risk of arrhythmias when combined with other inotropes or arrhythmogenic drugs
- Potential pharmacokinetic interactions with potent CYP inhibitors or inducers (minor role)
Curated Content: Needs Vetting Before Put to Clinical Use